Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.72 |
| ▸ | GRM8 | O00222 | 2/20 | 0.72 |
| ▸ | GRM6 | O15303 | 2/20 | 0.72 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.72 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.72 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.72 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.72 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.72 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.72 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.72 |
| ▸ | GSR | P00390 | 1/20 | 0.72 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.72 |
| ▸ | GRM5 | P41594 | 1/20 | 0.72 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.72 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.72 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.72 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.72 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.72 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.72 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| D-Glutamate SCHEMBL109452 | 1.00 | CYP1A2 (0.72) | CYP1A2GRM8GRM6GRM7GRM4 | |
| Glutamic Acid SCHEMBL27972370 | 1.00 | CYP1A2 (0.72) | CYP1A2GRM8GRM6GRM7GRM4 | |
| Glutamic Acid SCHEMBL3884421 | 0.96 | CYP1A2 (0.67) | CYP1A2GRM8GRM6GRM7GRM4 | |
| Glutamic Acid SCHEMBL2062621 | 0.93 | SLC1A3 (0.62) | CYP1A2GRM8GRM6GRM7GRM4 | |
| Glutamic Acid SCHEMBL3633547 | 0.93 | SLC1A3 (0.62) | CYP1A2GRM8GRM6GRM7GRM4 | |
| Glutamic Acid SCHEMBL1965776 | 0.91 | CYP1A2 (0.60) | CYP1A2GRM8GRM6GRM7GRM4 | |
| D-Glutamate SCHEMBL1965774 | 0.91 | CYP1A2 (0.60) | CYP1A2GRM8GRM6GRM7GRM4 | |
| Glutamic Acid SCHEMBL6465269 | 0.88 | CYP1A2 (0.56) | CYP1A2GRM8GRM6GRM7GRM4 | |
| Glutamine SCHEMBL17926810 | 0.88 | ALOX15 (0.59) | CYP1A2GRM8GRM6GRM7GRM4 | |
| D-Glutamate SCHEMBL6696831 | 0.87 | CYP1A2 (0.86) | CYP1A2GRM8GRM6GRM7GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114480393-A | Globulin gene therapy for the treatment of hemoglobinopathies | 纪念斯隆-凯特琳癌症中心 | 2022-05-13 | — | — | CN | disclosed |
| CN-114457076-A | Globulin gene therapy for the treatment of hemoglobinopathies | 纪念斯隆-凯特琳癌症中心 | 2022-05-10 | — | — | CN | disclosed |
| CN-107208093-B | Globulin gene therapy for the treatment of hemoglobinopathies | 纪念斯隆-凯特琳癌症中心 | 2022-03-01 | — | — | CN | disclosed |
| US-11180812-B2 | Use of DNA in circulating exosomes as a diagnostic marker for metastatic disease | CORNELL UNIVERSITY (US) | 2021-11-23 | — | — | US | disclosed |
| US-10844436-B2 | Use of double-stranded DNA in exosomes: a novel biomarker in cancer detection | CORNELL UNIVERSITY (US) | 2020-11-24 | — | — | US | disclosed |
| US-10175233-B2 | Biomarkers for cardiovascular diseases and methods using the same | METABOLON, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10005831-B2 | Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof | JANSSEN VACCINES & PREVENTION B.V. (NL) | 2018-06-26 | — | — | US | disclosed |
| EP-3237612-A1 | SEQUENCE VARIANTS | Sandoz AG (CH) | 2017-11-01 | — | — | EP | disclosed |
| CN-107208093-A | Globulin gene therapy for the treatment of hemoglobinopathies | 纪念斯隆-凯特琳癌症中心 | 2017-09-26 | — | — | CN | disclosed |
| US-20170175200-A1 | USE OF DOUBLE-STRANDED DNA IN EXOSOMES: A NOVEL BIOMARKER IN CANCER DETECTION | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2017-06-22 | — | — | US | disclosed |
| US-8029802-B2 | Vaccines against Japanese encephalitis virus and West Nile virus | SANOFI PASTEUR BIOLOGICS CO. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20110070235-A1 | COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF INFLUENZA | THERACLONE SCIENCES, INC. | 2011-03-24 | — | — | US | disclosed |
| WO-2010126993-A1 | IMMUNOREACTIVE EHRLICHIA P120/P140 EPITOPES AND USES THEREOF | RESEARCH DEVELOPMENT FOUNDATION (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20090155826-A1 | Biomarkers for pre-diabetes, cardiovascular diseases, and other metabolic-syndrome related disorders and methods using the same | METABOLON, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20070269458-A1 | Vaccines Against Japanese Encephalitis Virus and West Nile Virus | ACAMBIS INC. (US) | 2007-11-22 | — | — | US | disclosed |
| US-20020001804-A1 | Genomic analysis of tRNA gene sets | TAO BIOSCIENCES, LLC | 2002-01-03 | — | — | US | disclosed |
| US-6306591-B1 | ANALYZING SAMPLE OF DNA FROM SHEEP WITH OLIGONUCLEOTIDE PROBE TO DETERMINE PRESENCE OR ABSENCE OF POLYMORPHISM IN FIBROBLAST GROWTH FACTOR RECEPTOR 3 GENE | UTAH STATE UNIVERSITY | 2001-10-23 | — | — | US | disclosed |
| US-5770560-A | TREATING REDUCED HEMOGLOBIN OXYGEN AFFINITY IN MAMMALS | Fischer, James J. (US) | 1998-06-23 | — | — | US | disclosed |
| US-5173426-A | Pure polynucleotide; for increasing tissue oxygenation in patients | YALE UNIVERSITY (US) | 1992-12-22 | — | — | US | disclosed |
| US-3956040-A | Explosive slurry composition containing sodium montmorillonite | GELAN KABUSHIKI KAISHA (JA) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110070235-A1 | COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF INFLUENZA | HAVCR2, NEU2, CD44 | CYP1A2 2316/4885GRM8 4696/4885GRM6 4225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.